- Report
- May 2025
- 110 Pages
Global
From €4485EUR$4,750USD£3,744GBP
- Report
- June 2025
- 150 Pages
Global
From €3541EUR$3,750USD£2,956GBP
- Report
- April 2025
- 80 Pages
Global
From €1888EUR$2,000USD£1,576GBP
- Report
- August 2024
- 60 Pages
Global
From €1416EUR$1,500USD£1,182GBP
- Report
- July 2024
- 150 Pages
Global
From €3541EUR$3,750USD£2,956GBP
- Report
- July 2024
- 150 Pages
Global
From €3541EUR$3,750USD£2,956GBP
- Report
- July 2024
- 100 Pages
Global
From €3541EUR$3,750USD£2,956GBP
- Report
- January 2022
- 90 Pages
Global
From €1888EUR$2,000USD£1,576GBP
- Report
- January 2022
- 90 Pages
Global
From €1888EUR$2,000USD£1,576GBP
- Report
- January 2022
- 60 Pages
Global
From €1888EUR$2,000USD£1,576GBP
- Report
- January 2022
- 150 Pages
Global
From €1416EUR$1,500USD£1,182GBP
- Report
- January 2022
- 60 Pages
Global
From €1416EUR$1,500USD£1,182GBP
- Report
- January 2022
- 60 Pages
Global
From €1416EUR$1,500USD£1,182GBP
- Report
- January 2022
- 60 Pages
Global
From €1416EUR$1,500USD£1,182GBP
- Report
- January 2022
- 70 Pages
Global
From €944EUR$1,000USD£788GBP
- Report
- July 2025
- 200 Pages
India
From €2633EUR$2,789USD£2,198GBP
- Report
- June 2025
- 400 Pages
Global
From €4673EUR$4,949USD£3,901GBP
- Report
- June 2025
- 250 Pages
United States
From €2633EUR$2,789USD£2,198GBP
- Report
- June 2023
- 120 Pages
Asia Pacific
From €3653EUR$3,869USD£3,050GBP
- Report
- May 2023
- 140 Pages
Global
From €4673EUR$4,949USD£3,901GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more